Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

Eur J Haematol. 2023 Feb;110(2):222-223. doi: 10.1111/ejh.13896. Epub 2022 Nov 20.

Authors

Bernard Sean Regidor¹, Dilawer Siddiqi¹, Bethany Marie Beatty¹, Marissa-Skye Goldwater², Scott Jew^{1

2}, Sean Bujarski^{1

2}, Regina Swift¹, Susanna Kim³, James R Berenson^{1

2

3}

Affiliations

¹ Berenson Cancer Center, West Hollywood, California, USA.
² Institute for Myeloma and Bone Cancer Research, West Hollywood, California, USA.
³ Oncotherapeutics, West Hollywood, California, USA.

PMID: 36367357
DOI: 10.1111/ejh.13896

No abstract available

Keywords: anti-CD38; daratumumab; multiple myeloma; venetoclax.

Publication types

Letter

MeSH terms

ADP-ribosyl Cyclase 1
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics

Substances

ADP-ribosyl Cyclase 1
Antibodies, Monoclonal
Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
venetoclax
CD38 protein, human